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Protein kinase CCardiac sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCA2a) promotes Ca2+ uptake in the SR. Dephosphorylated
phospholamban (PLB) inhibits SERCA2a activity. We found a distinct dephosphorylation of PLB at Thr17 and Ser16
after 20–30 min of ischemia produced by coronary artery occlusion in rats. The aim of the studywas to investigate
how PLB is dephosphorylated in ischemia and to determine whether PLB dephosphorylation causes myocardial
hypercontraction and calpain activation through Ca2+ overload in reperfusion. Protein inhibitor-1 (I-1) speciﬁcally
inhibits protein phosphatase 1 (PP1), the predominant PLB phosphatase in heart. A Ca2+-dependent phosphatase
calcineurinmay also induce PLB dephosphorylation. Ischemia for 30 min induced PKC-α translocation, resulting in
inactivationof I-1 throughPKC-α-dependentphosphorylationat Ser67. ThePP1activation following I-1 inactivation
was thought to induce PLB dephosphorylation in ischemia. Ischemia for 30 min activated calcineurin, and pre-
treatment with a calcineurin inhibitor, cyclosporine A (CsA), inhibited PKC-α translocation, I-1 phosphorylation at
Ser67, and PLB dephosphorylation in ischemia. Reperfusion for 5 min following 30 min of ischemia induced
spreading of contraction bands (CBs) and proteolysis of fodrin by calpain. Both CsA and an anti-PLB antibody that
inhibits bindingof PLB to SERCA2a reduced theCBarea and fodrinbreakdownafter reperfusion. These results reveal
a novel pathway viawhich ischemia induces calcineurin-dependent activation of PKC-α, inactivation of I-1 through
PKC-α-dependent phosphorylation at Ser67, and PP1-dependent PLB dephosphorylation. The pathway contributes
to the spreading of CBs and calpain activation through Ca2+ overload in early reperfusion.-ku, Tokyo 113-0033, Japan.
shida).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCA2a) uptakes Ca2+
into the SR, thereby regulating the cytosolic Ca2+ concentration and the
rate of contraction and relaxation in the heart. Phospholamban (PLB)
inhibits ventricular SERCA2a activity through binding to SERCA2a.
WhenPLB is phosphorylatedat Thr17 by calmodulin-dependentkinase II
(CAMKII) and at Ser16 by protein kinase A (PKA), SERCA2a is activated
upon release from its complex with PLB. Sustained SERCA2a activation
through PLB phosphorylation underlies the enhanced cardiac contrac-
tility in the β-adrenergic response through enhanced SR Ca2+ loading
[1].
In failing hearts, PLB is dephosphorylated and binds to SERCA2a,
thereby depressing contractility through inhibition of the SR Ca2+
uptake [2–4]. Inhibition of PLB dephosphorylation by okadaic acid, a
protein phosphatase inhibitor [5], inhibition of the PLB-SERCA2a
interaction by PLB-targeted antibodies [6,7], or antisense ablation of
PLB [8] improves cardiac contractility via enhanced SR Ca2+ loading
facilitated by SERCA2a in the failing heart. These ﬁndings are consistent
with the hypothesis that the SR acts as a Ca2+ sink for an excessiveintracellular Ca2+ and that compromised SR uptake of Ca2+may render
cardiomyocytes sensitive to the intracellular Ca2+ overload.
In the heart, protein phosphatase 1 (PP1) is the predominant PLB
phosphatase [5,9], and protein inhibitor 1 (I-1) is the main inhibitor of
PP1 [10,11]. I-1 is activated by phosphorylation at Thr35 by PKA, with
resultant inhibition of PP1 activity [12–14], and is inhibited by protein
kinase C (PKC)-dependent phosphorylation at Ser67 and/or Thr75 [15–
17]. PKC activation is accompanied by translocation between subcellular
compartments. In an ischemic perfused rat heart, we showed
translocation of PKC-α and -ε from the cytosolic fraction to the
particulate fraction [18].
Few reports support the involvement of a Ca2+-dependent phos-
phatase, calcineurin in PLB dephosphorylation. In the spontaneously
hypertensive rat, a calcineurin inhibitor, cyclosporinA (CsA), normalizes
blunted β-adrenergic responsiveness by prevention of PLB dephos-
phorylation and improvement of SR Ca2+ handling [19]. In dilated
cardiomyopathic hearts, enhanced calcineurin activity mediates re-
ductions in SERCA2a activity and SR Ca2+ uptake, and suggested that
calcineurin directly dephosphorylates PLB at Thr17 [4]. Calcineurin is
activated in acute myocardial ischemia [20].
There are few reports on the calcineurin-dependent PKC activation
in hearts. In cardiomyocytes, calcineurin is necessary for stretch-
induced PKC-ε translocation [21]. In transgenic mice overexpressing
N-terminal fragment of Kv4.2 (Kv4.2N), calcineurin is activated and
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inﬂux [22]. In calcineurin overexpressing transgenic mice, calcineurin
induces activation of PKC-α and -θ, and is involved in hypertrophic
response [23].
During the ﬁrst minutes of post-ischemic reperfusion, cardiomyo-
cytes undergo intercellular Ca2+ overload [24], resulting in propaga-
tion of contraction bands (CBs), a hallmark of Ca2+-dependent
myocardial hypercontraction [25], and in proteolysis of α-fodrin, a
cytoskeletal protein by a Ca2+-dependent protease, calpain [26]. The
current study was based on our ﬁnding of the marked dephosphor-
ylation of PLB at Thr17 and Ser16 after brief ischemia.We sought to ﬁnd
the link between PLB dephosphorylation during ischemia and Ca2+
overload during reperfusion.
In this study, we tested the hypothesis that brief ischemia induces
calcineurin activation, PKC-α activation, PKC-α-dependent phosphor-
ylation at Ser67 of I-1 and inactivation of I-1, PP1 activation, and PLB
dephosphorylation in an in vivo model of acute myocardial infarction.
To address the role of these pathways in Ca2+ overload during early
reperfusion, CBs and calpain-mediated fodrin proteolysis were exam-
ined after brief reperfusion.
2. Materials and methods
2.1. Animal model
The investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH publication 85–23, revised 1996) and was approved by the
Institutional Animal Care and Use Committee of the University of
Tokyo. The left anterior descending coronary artery (LAD) of male
Sprague–Dawley rats aged 8 weeks was occluded. An ECG (lead II)
was monitored throughout the experiment. Rats in which arrhythmic
events (PVCs, short runs of VT, and occurrence of VF) occurred during
the early period (5 to 10 min) of ischemia were used in subsequent
analyses. After the experiment, 1% Evans blue (EB) dye was injected
into the right atrium to demarcate the risk area in the heart. The heart
was divided into risk (negative staining with EB) and non-risk
(positive staining with EB) areas, and each specimen was stored. In
further experiments, CsA (25 mg/ml/kg in saline, i.p. [27]) or Gö6976
(100 μg in 8 μl dimethylformamide, s.c. [28]) was injected 30 min
before LAD occlusion, or FK506 (3.5 mg/0.1 ml/kg in dimethylforma-
mide, i.v. bolus) was administered 15 min before LAD occlusion [20].
2.2. Sample preparation for Western blot analysis
For Western blotting, frozen heart tissue (0.1 g) was homogenized
with 1 ml of ice-cold STE buffer containing 320 mMsucrose, 10 mMTris–
HCl (pH 7.4), 1 mM EDTA, 50 mM NaF, 1 mM Na3VO4 and Complete
Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany). To
examinePKC translocation, thehomogenatewascentrifugedat10,000×g
for 10 min, and the supernatantwas further centrifuged at 100,000×g for
60 min. The 10,000×g pellet was suspended in ice-cold STE buffer in a
ﬁnal volume of 1 ml. The 100,000×g supernatant and 10,000×g pellet
fractions are referred to as the cytosolic fraction and particulate fraction,
respectively [18].
To enrich I-1 from heart tissues for Western blot detection,
trichloroacetic acid (TCA) extraction was performed [13]. Brieﬂy, frozen
heart tissue (0.2 g) was homogenized with 2 ml of ice-cold 1.5% TCA
containing 4 mM EDTA and centrifuged at 20,000×g for 30 min (unless
otherwise speciﬁed). The supernatant was mixed with TCA at a ﬁnal
concentration of 19%, and themixture was incubated at 4 °C for 16 h and
centrifuged. The pellet was resuspended in 500 nM Tris–HCl (pH 8.0),
boiled for 10 min, and centrifuged. The supernatantwas dialyzed for 16 h
against distilled water at 4 °C, centrifuged, and frozen at −80 °C until
further use.Protein concentrations were determined by the Bradford method
using aCoomassie ProteinAssayKit (ThermoFisher Scientiﬁc,Waltham,
MA).
2.3. Western blot analysis
The homogenate (25 μg protein for PLB and fodrin, 50 μg formouse
IgG) was subjected to SDS-PAGE on a 15% (PLB), 6.5% (fodrin) or
12.5% (mouse IgG) gel. For I-1, the TCA extract (5 μg protein) was
subjected to SDS-PAGE on a 15% gel. To examine PKC translocation,
the homogenate (5 μg protein), the cytosolic fraction (30 μg), and
the particulate fraction (20 μg) were subjected to SDS-PAGE on 7.5%
gels. Antibodies to P-Thr17 PLB, P-Ser16 PLB, SERCA2a, P-Thr35 I-1, P-
Ser67 I-1, and PKC-θ were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA), anti-total PLB antibody was purchased from
Calbiochem (Darmstadt, Germany), antibodies to PKC-α and -ε
were obtained from BD Biosciences (Franklin Lakes, NJ), and anti-
total α-fodrin antibody was purchased from Biohit (Helsinki,
Finland). An antibody for detection of the fodrin 150 kDa fragment
[29,30] was a generous gift from Dr. K Inomata (Tokyo Metropolitan
Institute of Gerontology, Tokyo, Japan). For chemiluminescence
detection, peroxidase-conjugated anti-mouse, -rabbit, or -goat IgG
was used (Promega, Madison,WI). The band densities weremeasured
using CS analyzer 3 (Atto, Tokyo, Japan). The protein level of the target
was determined from a standard curve constructed by plotting the
band densities.
2.4. Measurement of calcineurin activity
Calcineurin activity was measured using a calcineurin activity assay
kit (BioMol, Plymouth Meeting, PA) according to the instructions
provided by the manufacturer. In brief, frozen tissues were homoge-
nized in ice-cold lysis buffer and centrifuged at 10,000×g for 45 min.
Phosphatase activity in the supernatant (0.5 mg protein/ml) was
measured using RII Phosphopeptide as a calcineurin-speciﬁc substrate
in the presence or absence of 10 mM EGTA. The phosphatase activity
with EGTA treatment was subtracted from that without EGTA
treatment, and the subtracted phosphatase activity was regarded as
calcineurin activity.
2.5. In vivo anti-PLB antibody injection
A mouse anti-PLB monoclonal antibody 2D12 (Abcam, Cambridge,
UK) was injected into rat hearts using a hemagglutinating virus of
Japan (HVJ)-envelope vector. The vector was provided by Ishihara
Sangyo Kaisha (Osaka, Japan) and prepared as previously described
[31]. HVJ-envelope vector (0.63 AU in 200 μl saline) containing the
antibody (12.5 μg) was transfected into the heart at 4 sites (50 μl at
each site) 1 h before LAD occlusion. As a control, an empty vector or a
vector containing mouse IgG (IgG2a monoclonal, Abcam) was
injected. To conﬁrm induction of IgG in heart tissues, Western blots
of the heart homogenate were probedwith peroxidase-conjugated rat
anti-mouse IgGwith negligible cross-reactivitywith rat serumprotein
(Jackson ImmunoResearch, West Grove, PA).
2.6. Immunoﬂuorescence analysis
To examine the subcellular localization of the injected anti-PLB
antibody, immunohistochemical staining for mouse IgG and SERCA2a
was performed. Transverse sections of the heart were immersed in 8%
formaldehyde, embedded in parafﬁn, and sectioned at a thickness of
3 μm. The sections were deparafﬁnized and subjected to microwave
treatment with citrate buffer for 5 min to expose antigen binding sites.
The sections were then incubated overnight with goat anti-SERCA2a
antibody (Santa Cruz Biotechnology) diluted 1:50, and then for 1 hwith
Alexa Fluor 569F(ab′) fragment anti-goat IgG (as a secondary antibody
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injected anti-PLB antibody) (Invitrogen, Carlsbad, CA), each diluted
1:100. Fluorescence was observed with a confocal laser scanning
microscope (Fluoview FV300, Olympus, Tokyo, Japan).
2.7. SR Ca2+ uptake assay
Cardiac SR vesicles were prepared according to themethod of Vittone
et al. [32]. The Ca2+ uptake capacity of the vesicles was measured as
previously described [33]. Brieﬂy, SR vesicles (0.2 mg/ml)were incubated
with 2.5 μM ﬂuo-3 (Dojindo, Kumamoto, Japan) solution containing
0.15 mMpotassiumgluconate, 1 mMMgCl2, 0.2 mMEGTA-calciumbuffer
(free [Ca2+] 0.3 μM), 10 mM NaN3, and 20 mM MOPS, pH 6.8. Upon
addition of 0.5 mM ATP, the ﬂuo-3 ﬂuorescence is reduced by SR Ca2+
uptake. The ﬂuorescence was monitored using a plate-reader (GENios,
Tecan, Männedorf, Switzerland) with excitation at 485 nm and emission
at 535 nm.
2.8. Measurement of the CB area
The CB area wasmeasured 5 min after reperfusion following 30 min
of ischemia, as described previously [25]. After the 3 μm sections wereFig. 1. Temporal changes of P-Thr17, P-Ser16 and total PLB levels during ischemia. Panel A show
internal control). Panel B shows the band densities of P-Thr17, P-Ser16 and total PLB relative to th
risk area; PLBp, pentameric PLB; PLBm, monomeric PLB. ⁎⁎, pb0.01 vs. sham (Dunnett's test).stained with phosphotungstic acid hematoxylin (PTAH), the hypereo-
sinophilic CB bands were measured. CB-positive cells were marked
using digital image editing software Photoshop 6.0 (Adobe Systems, San
Jose, CA). The risk area and the CB areaweremeasured using Image-Pro
Plus (Media Cybernetics, Bethesda, MD).
2.9. Statistical analysis
Group data are expressed as the means±SE. The data were
analyzed using Dunnett's test, the Tukey–Kramer test, or Student's t-
test at a conﬁdence level of 95%.
3. Results
3.1. Effects of calcineurin inhibitors on PLB dephosphorylation in
ischemia
Western blots probed with antibody to total PLB showed a major
pentameric band (30 kDa, PLBp) and a minor monomeric band (6 kDa,
PLBm) (Fig. 1A). Western blots probed with speciﬁc antibodies
demonstrated that PLB phosphorylated at Thr17 (P-Thr17 PLB) or Ser16
(P-Ser16 PLB) markedly decreased in the risk areas after 20–30 min ofs representativeWestern blots for P-Thr17, P-Ser16 and total PLB, SERCA2a and actin (as an
emean of the sham group. Values are shown asmeans±SE (n=4). R, risk area; NR, non-
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previous reports that phosphorylation of PLB promotes aggregation of
PLB monomers into pentamers [34,35], monomeric PLB (PLBm)
increased in the risk areas after 20 and 30 min of LAD occlusion (total
PLB in Fig. 1A), whereas total PLB level (PLBp+PLBm) was unaltered
throughout ischemia (total PLB, in Fig. 1B). There was no signiﬁcant
change in the SERCA2a level throughout ischemia. Ischemia for 30 min
decreased P-Thr17 and P-Ser16 PLB levels to about 20% and 30% of
the sham levels, respectively (Fig. 2). However, administration of
a calcineurin inhibitor, CsA, before ischemia restored the P-Thr17 and
P-Ser16 PLB levels in the risk area to about 70% and 95% of the sham
levels, respectively, after 30 min of ischemia (Fig. 2A). In the non-risk
area, CsA had no effect on PLB phosphorylation (data not shown). A
more speciﬁc calcineurin inhibitor, FK506, also abolished the post-
ischemic dephosphorylation of PLB at Thr17 and Ser16 (Fig. 2B).
Additionally, calcineurin activity increased in 30 min of ischemia, and
the activation was inhibited by the CsA pre-treatment (Fig. 2C). These
results suggest involvement of calcineurin in PLB dephosphorylation in
ischemia.Fig. 2. Effect of CsA (Panel A) or FK506 (Panel B) administration onPLBdephosphorylation
and calcineurin activity (Panel C) in 30 min of ischemia. Values are shown as means±SE
(n=6). DMF, dimethylformamide. ⁎, pb0.05; ⁎⁎, pb0.01 (Tukey–Kramer test).3.2. Translocation of PKC-α in ischemia
After 30 min of ischemia, the PKC-α level decreased in the
cytosolic fraction (Fig. 3B) and increased in the particulate fraction
(Fig. 3C), but was unaltered in the homogenate (Fig. 3A). PKC-α is
activated upon translocation in the risk area and pretreatment with
CsA inhibited this translocation of PKC-α during ischemia (Fig. 3A–C).
There was no PKC-α redistribution in non-risk area, irrespective of
CsA pre-treatment (data not shown). It has also been reported that
calcineurin induces translocation of PKC-ε [21] and -θ [22,23].
However, we found that neither ischemia nor CsA had an effect on
the distribution of PKC-ε or -θ (Fig. 3D).
Treatment with a synthetic PKC-α inhibitor, Gö6976, before LAD
occlusion inhibited reduction of the levels of P-Thr17 and P-Ser16 PLB
in 30 min of ischemia (Fig. 3E). These results indicate that calcineurin-
dependent activation of PKC-α contributes to PLB dephosphorylation
in ischemia.
3.3. Effects of ischemia and CsA administration on I-1 activity
Phosphorylation of I-1 at Ser67 by PKC-α results in inactivation of I-
1 [15], whereas phosphorylation at Thr35 by PKA leads to activation of
I-1 [12]. Ischemia for 30 min increased I-1 phosphorylation at Ser67 to
2.5-fold (Fig. 4A) and decreased I-1 phosphorylation at Thr35 to about
5% (Fig. 4B) compared with sham treatment. CsA pretreatment
abolished I-1 phosphorylation at Ser67 (Fig. 4A), but had no effect on
dephosphorylation of I-1 at Thr35 in ischemia (Fig. 4B). These results
indicate that calcineurin-PKC-α-dependent phosphorylation of I-1 at
Ser67 contributes to PLB dephosphorylation in ischemia.
3.4. Relationship between PLB dephosphorylation and Ca2+ overload in
reperfusion
PLB dephosphorylation and reduced SR Ca2+ uptake through
SERCA2a inactivation in ischemia are likely to contribute to Ca2+
overload in early reperfusion. CB develops through Ca2+ overload in
the ﬁrst minutes of reperfusion [24] and we previously found that
reperfusion following brief ischemia induces calpain-mediated pro-
teolysis of fodrin (250 kDa) to the 150 kDa fragment [26]. After 5 min
of reperfusion following 30 min of ischemia, CBs occupied about 20%
of the risk area (empty+IR group in Fig. 6A, empty group in Fig. 6B).
Reperfusion induced fodrin proteolysis with an increase in the
150 kDa fragment (saline groups in Fig. 7A and B).
The monoclonal anti-PLB antibody 2D12 was shown previously to
block formation of the PLB complex with SERCA2a [7,36]. To examine
whether PLB dephosphorylation in ischemia contributes to Ca2+
overload in reperfusion, we injected the risk area with the anti-PLB
monoclonal antibody using the HVJ-envelope vector before ischemia
and evaluated the CB area and fodrin degradation. Introduction of the
antibody was conﬁrmed by immunohistochemistry 1 h after the
injection. Mouse IgG (injected anti-PLB antibody 2D12) immunoﬂu-
orescence and SERCA2a immunoﬂuorescence were co-distributed to
the striations after the injection of the antibody (Fig. 5A), reﬂecting
the presence of the antibody in the SR. Additionally, Western blot
analysis showed the presence of the mouse IgG in the risk area after
anti-PLB antibody or IgG2a (as a control IgG) injection, but not in the
non-risk area or in the risk area of the group injected with an empty
vector (Fig. 5B).
Next, to examine whether the injected anti-PLB antibody blocks
formationof the PLB-SERCA2a complex,wemeasuredCa2+uptake in SR
vesicles isolated from heart injected with anti-PLB antibody (2D12) or
control IgG (IgG2a). After 30 min of ischemia, the amount of SR Ca2+
uptake in the risk area of IgG2a group decreased (70% vs. sham)
(Fig. 5C). Injection of 2D12 antibody blunted the decrease in the Ca2+
uptake (Fig. 5C).
Fig. 3. Translocation of PKC isoforms in30 min of ischemia. Panels A, B andC showPKC-α levels inwhole (standard homogenate), cytosolic andparticulate fractions, respectively, prepared
from the risk areas of hearts subjected to 30 min of ischemia. Values are shownasmeans±SE (n=4). ⁎, pb0.05; ⁎⁎, pb0.01 (Tukey–Kramer test). Panel D shows PKC-ε and -θ levels in the
cytosol and particulate fractions. Values are shown asmeans±SE (n=4). I, ischemia. Therewere no signiﬁcant differences among the sham, I+saline and I+CsA groups in any fractions
(Tukey–Kramer test). Panel E shows the effect of Gö6976 administration on PLB dephosphorylation in 30 min of ischemia. Values are shown as means±SE (n=4). DMF,
dimethylformamide. ⁎, pb0.05; n.s., no signiﬁcant (Tukey–Kramer test).
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occupied about 20% of the risk area in hearts injected with empty
vectors (empty+IR group in Fig. 6A, empty group in Fig. 6B). Injection
of anti-PLB antibody decreased the CB area to about 4% of the risk area
(2D12+IR group in Fig. 6A, 2D12 group in Fig. 6B), but injection of
IgG2a had no effect on the CB area (IgG2a group in Fig. 6A, IgG2a group
in Fig. 6B). There was no difference in the risk area between each group
(Fig. 6B). In the sham-operated heart, injection of the anti-PLB antibody
did not induce CBs (2D12+sham group in Fig. 6A). Dephosphorylation
of PLB was not reduced after reperfusion for 5 min, compared with
ischemia for 30 min (Figs. 6C and 1). Additionally, PLB dephosphory-
lation in the risk area was not affected by the antibody injection
(Fig. 6C).Reperfusion for 5 min also induced fodrin proteolysis with
generation of the 150 kDa fragment, and this was blocked by anti-
PLB antibody (Fig. 7A and B). Moreover, CsA pre-treatment reduced
the CB area (Fig. 6D) and fodrin degradation (Fig. 7) after reperfusion.
These results support the hypothesis that calcineurin-mediated PLB
dephosphorylation during ischemia contributes to Ca2+ overload-
mediated injury in early reperfusion, which manifests as CB
development and fodrin proteolysis.
4. Discussion/conclusion
The results of this study suggest the presence of a novel pathway
involving calcineurin, PKC-α, I-1 and PP1 in dephosphorylation of PLB
Fig. 4. Effect of CsA administration on I-1 phosphorylation in 30 min of ischemia. Panels
A and B show the relative levels of P-Ser67 and P-Thr35 I-1, respectively. Values are
shown as means±SE (n=4). ⁎⁎, pb0.01 (Tukey–Kramer test).
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myocardial hypercontraction (contraction band, CB) and calpain
activation due to Ca2+ overload in early reperfusion. CsA inhibitedFig. 5. Injection of anti-PLB antibodies into the myocardium. Panel A shows
representative images of mouse IgG or SERCA2a immunoﬂuorescence in hearts 1 h
after injection of empty vector or anti-PLB monoclonal antibody 2D12. Panel B shows a
representative Western blot of mouse IgG in hearts injected with empty vector or
vector containing 2D12 or IgG2a. IgG, puriﬁed mouse IgG was used in the Western blot
analysis as a molecular weight control. Panel C shows Ca2+ uptake of SR vesicles
prepared from hearts subjected to 30 min of ischemia following injection of 2D12 or
IgG2a. Values are shown as mean±SE (n=6).
Fig. 6. Effect of anti-PLB antibody injection or CsA administration on the CB area in
5 min of reperfusion following 30 min of ischemia. Panel A shows the area of CB
(marked in black) in transverse sections of hearts that underwent ischemia–
reperfusion (IR) following injection with empty vector (empty+IR), 2D12 antibody
(2D12+IR), or IgG2a (as IgG control, IgG2a+IR). “2D12+sham” refers to sham-
operated hearts injected with 2D12 antibody. The borders of the risk and non-risk areas
are indicated by dotted lines. Panel B shows the ratio (%) of the risk area (RA) to the left
ventricular (LV) area and the ratio of the CB area (CA) to the RA. Values are shown as
means±SE (n=6). ⁎⁎, pb0.01 vs. empty vector (Dunnett's test). Panel C shows
Western blots of P-Thr17 and P-Ser16 PLB in the hearts presented in panel A. R, risk area;
NR, non-risk area; S, sham. Panel D shows the ratios (%) of the risk and CB areas. Values
are shown as means±SE (n=6). ⁎⁎, pb0.01 vs. saline (Student's t-test).every step in this pathway: activation of PKC-α, phosphorylation of
I-1 at Ser67, and dephosphorylation of PLB at Ser16 and Thr17 during
brief ischemia; and CB development and calpain activation during
early reperfusion. FK506, a more speciﬁc calcineurin inhibitor, also
inhibited PLB dephosphorylation at Ser16 and Thr17 after ischemia.
Fig. 7. Effect of anti-PLB antibody injection or CsA administration on calpain activation
after 5 min of reperfusion following 30 min of ischemia. Panel A shows representative
Western blots detected with anti-total fodrin antibody or anti-the fodrin 150 kDa
fragment antibody. Panel B shows the relative band densities of the fodrin 150 kDa
fragment to the intact fodrin (250 kDa). Values are shown as means±SE (n=4). R, risk
area; NR, non-risk area. ⁎⁎, pb0.01 vs. the risk area in the saline group (Dunnett's test).
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inducedmarked dephosphorylation of PLB at Ser16 and Thr17. There are
a few reports on PLB dephosphorylation in ischemia–reperfusion with
respect to hypertrophy or heart failure after myocardial infarction
[11,37,38]. However, suchmarked PLB dephosphorylation has not beenIschemia
Calcineurin activation
PKC-α activation a
I-1 Ser67 phosphorylation a
I-1 inactivation
PP-1 activation
PLB dephosphorylation a, b, c
PLB-SERCA2a complex formation
SR Ca2+ uptake inhibition
Cytosolic Ca2+ overload








Fig. 8. Proposed pathway of calcineurin-mediated PLB dephosphorylation during
ischemia. The steps at which CsA, FK506, Gö6976 and anti-PLB antibody show inhibitive
effects are indicated by a, b, c and d, respectively.shown previously in an in vivo or ex vivo model of ischemia. This
discovery may provide a breakthrough to a better understanding of the
mechanism of formation of myocardial lesions and injury in acute
ischemia–reperfusion. Ischemia induced dephosphorylation of I-1 at
Thr35 and phosphorylation at Ser67 (Fig. 4), either of which can
inactivate I-1 [13,15]. CsA pre-treatment almost abolished dephosphor-
ylation of PLB (Fig. 2) and phosphorylation of I-1 at Ser67 (PKC-α site)
(Fig. 4), but had no effect on dephosphorylation at Thr35 (PKA site) in
ischemic heart. Therefore, phosphorylation of I-1 at Ser67 is likely to play
a pivotal role in PLB dephosphorylation in ischemia. This study also
showed a new pathway for regulation of PLB phosphorylation through
PKC phosphorylation of I-1 downstream of calcineurin.
In neonatal rat cardiomyocytes, El-Armouche et al. demonstrated
that calcineurin and PP2A constantly dephosphorylate I-1 at Thr35
[39]. In this study, the ineffectiveness of CsA (Fig. 4) suggests that
PP2A rather than calcineurin contributes to the dephosphorylation of
I-1 at Thr35 in ischemia. PKC-α can phosphorylate not only Ser67 but
also Thr75 on I-1 [16], and the phosphorylation of either site induces
inactivation of I-1 and promotion of PP1-dependent dephosphoryla-
tion of PLB at Ser16 [16,17]. The possible contribution of the
phosphorylation of I-1 at Thr75 could not be neglected because of
the lack of commercially available antibody. However, the nearly
complete inhibition of the phosphorylation of I-1 at Ser67 (Fig. 4) and
PLB dephosphorylation (Fig. 2) by CsA supports that Ser67 of I-1 is
involved in PLB dephosphorylation in ischemia.
Ischemia induced PKC-α translocation to the particulate fraction in
vivo (Fig. 3), as previously reported [18]. The PKC-α translocation was
inhibited by CsA (Fig. 3A–C). Ischemia is well known to induce Ca2+
inﬂux [40] and activate calcineurin [41]. In calcineurin overexpressing
transgenic mice, calcineurin-dependent activation of PKC-α and -θ
was demonstrated, but it remains unclear whether the activated
calcineurin activates them directly or indirectly [23]. There is no
report on the direct interaction of calcineurin and PKC-α. However,
the activated calcineurin dephosphorylates L-type Ca2+-channels and
enhances the Ca2+ inﬂux [42], which can induce activation of a Ca2+-
dependent PKC-α isoform [18]. The contribution of PKC-α to
dephosphorylation of PLB at Ser16 and Thr17in ischemia for 30 min
was conﬁrmed by the effect of Gö6976, a relatively speciﬁc PKC-α
inhibitor (Fig. 3E). Involvement of other PKC isoforms (ε, θ) was
negated by the lack of ischemia-induced translocation of PKC-ε and -θ
and the lack of an effect of CsA on translocation of these two proteins
in ischemia (Fig. 3D).
I-1 is a speciﬁc and prominent inhibitor of PP1 in the heart [10].
Previous reports indicate PP1 activation in ischemia [5,43] and there are
several studies showing dephosphorylation of PLB by PP1. In cardio-
myocytes isolated fromratswith chronicmyocardial infarction, PP1was
suggested to induce PLBdephosphorylationbased on the increase in PP1
activity and inhibition of PLB dephosphorylation by okadaic acid [5].
Okadaic acid is an inhibitor of PP1 andPP2A, but is difﬁcult touse in vivo.
Additionally, active I-1 expression augmented contractile function and
recovery in ex vivo ischemia–reperfusion through SERCA2a activation
via inhibition of PP1-mediated PLB dephosphorylation, although PLB
dephosphorylation in ischemia was not shown in the study [36].
Collectively, these ﬁndings support a primary contribution of PP1 in the
PLB dephosphorylation in ischemia. Dephosphorylated PLB reduces SR
Ca2+ uptake by binding to SERCA2a in vitro [44]. In a failing human
heart, an increase in calcineurin expression is associated with
dephosphorylation of PLB at Thr17 and reduced SERCA2a activity [4].
In spontaneously hypertensive rat, CsA normalizes the impaired
contractile response to β-adrenergic stimulation through recovery of
PLB phosphorylation [19]. Treatment of cardiomyocytes with anti-PLB
monoclonal antibody enhances the rate of Ca2+ uptake and suppresses
the ability of β-adrenoceptor stimulation to enhance SR Ca2+ handling
[36]. In a cardiomyopathic hamster, gene transfer of a PLB-targeted
antibody improves Ca2+ handling and cardiac function [6]. Moreover,
targeted antisense ablation of PLB rescues Ca2+-overload-induced
750 K. Shintani-Ishida, K. Yoshida / Biochimica et Biophysica Acta 1812 (2011) 743–751contractile dysfunction in rats through SERCA2a activation [8].
However, the effect of anti-PLB antibody on reperfusion injury has not
been examined in any experimental setting. Reduced SR Ca2+ uptake
caused by PLB dephosphorylation with impaired Ca2+ handling in
ischemia is likely to induce reperfusion injury due to cytosolic Ca2+
overload during early reperfusion. Previously, we reported rapid
spreading of CBs in 5 min of reperfusion following 30 min of ischemia
in the samemodel [25].We also found that rapid proteolysis of fodrin by
calpain, a Ca2+-dependent protease, causes contractile dysfunction in
reperfusion followingbrief ischemia in perfusedheart [26]. In this study,
reperfusion for 5 min after 30 min of ischemia induced the development
of CBs and fodrin proteolysis (Figs. 6 and 7).We found that introduction
of anti-PLB antibody andCsA administration greatly reduced the CB area
(Fig. 6) and fodrin proteolysis (Fig. 7) in reperfusion. These results
support the hypothesis that a pathway leading to the PLB dephosphor-
ylation in ischemia causes Ca2+ overload in early reperfusion.Acknowledgements
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